ArticleAnnals of surgical oncology2026
The Use and Utility of Preoperative Somatostatin Receptor-Based Imaging in Gastroenteropancreatic Neuroendocrine Tumors.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundContemporary gastroenteropancreatic neuroendocrine tumor (GEPNET) management guidelines recommend routine use of functional imaging preoperatively, but there are few data highlighting trends in functional imaging adoption. This report reviews 24 years of neuroendocrine tumor (NET) experience to describe changes in rates of preoperative functional imaging use and highlights performance differences between functional imaging types in small bowel NETs (SBNET) and pancreatic NETs (PNETs).
methodsA retrospective single-institution study from 2000 to 2023 identified patients with SBNETs and PNETs treated with surgical resection, cytoreduction, or both who underwent preoperative functional imaging. The primary measurements were frequency of functional imaging use and location of metastases identified on preoperative imaging.
resultsThe study included 392 SBNET and 208 PNET patients. Preoperative functional imaging was performed for 248 (63.3%) SBNET patients (158 somatostatin receptor [SSTR] positron emission tomography [PET] and 90 Octreoscan) and 113 (54.3%) PNET patients (47 SSTR PET and 66 Octreoscan). There was a significant positive trend over time in functional imaging use in SBNET patients, with an approximate 2.5% yearly increase (p < 0.01) but no significant change in PNET patients during the course of the study (p = 0.82). At presentation, 82.3% (204/248) of the SBNET patients and 54.9% (62/113) of the PNET patients had metastatic disease. Compared with Octreoscan, SSTR PET more frequently identified bone and retroperitoneal nodal metastases.
conclusionRates of functional imaging use in SBNET patients but not in PNET patients increased significantly during the last 24 years. Patients with SBNETs and PNETs frequently presented with metastatic disease, and SSTR-based functional imaging was extremely helpful in identifying distant disease, intra-operative planning, and further management.
Indexed as
Identifiers
42886322What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.